FDA gives full approval to Alzheimer’s disease drug Leqembi
Jul 06, 2023
Although Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds.
Gut microbial taxonomic profiles differ with, without preclinical Alzheimer’s disease
Jun 16, 2023
A change in gut microbiome composition was associated with β-amyloid and tau pathological brain biomarkers.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
Causal link ID’d for Alzheimer’s disease, generalized epilepsy
May 25, 2023
A genetic predisposition to Alzheimer’s also is linked to an increased risk of focal epilepsy with hippocampal sclerosis.
Allopurinol may cut risk for neurodegenerative diseases
May 19, 2023
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
Medicare spending would increase $2.0 to $5.1 billion with lecanemab
May 18, 2023
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
Experimental drug for Alzheimer’s disease slows decline in thinking
May 03, 2023
Eli Lilly says the drug slows memory and thinking declines in early symptomatic Alzheimer’s disease patients by more than a third.
Vascular risk factors only explain part of Alzheimer’s disease risk for Blacks, Hispanics
Jan 11, 2023
Barriers to healthcare access and other socioeconomic factors may increase vulnerability in racial/ethnic minorities.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.
Natural environments may cut hospitalization for patients with neurodegenerative diseases
Dec 30, 2022
The normalized difference vegetation index was negatively associated with hospitalization for Alzheimer’s disease and related dementia as well as Parkinson’s disease.